University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA; Department of Otolaryngology, University of Ulm, Ulm, Germany.
Clin Exp Immunol. 2014 Aug;177(2):531-43. doi: 10.1111/cei.12354.
While murine CD4(+) CD39(+) regulatory T cells (T(reg)) co-express CD73 and hydrolyze exogenous (e) adenosine triphosphate (ATP) to immunosuppressive adenosine (ADO), surface co-expression of CD73 on human circulating CD4(+) CD39(+) T(reg) is rare. Therefore, the ability of human T(reg) to produce and utilize ADO for suppression remains unclear. Using mass spectrometry, we measured nucleoside production by subsets of human CD4(+) CD39(+) and CD4(+) CD39(-)CD73(+) T cells or CD19(+) B cells isolated from blood of 30 volunteers and 14 cancer patients. CD39 and CD73 expression was evaluated by flow cytometry, Western blots, confocal microscopy or reverse transcription-polymerase chain reaction (RT-PCR). Circulating CD4(+) CD39(+) T(reg) which hydrolyzed eATP to 5'-AMP contained few intracytoplasmic granules and had low CD73 mRNA levels. Only ∼1% of these T(reg) were CD39(+) CD73(+) . In contrast, CD4(+) CD39(neg) CD73(+) T cells contained numerous CD73(+) granules in the cytoplasm and strongly expressed surface CD73. In vitro-generated T(reg) (Tr1) and most B cells were CD39(+) CD73(+) . All these CD73(+) T cell subsets and B cells hydrolyzed 5'-AMP to ADO. Exosomes isolated from plasma of normal control (NC) or cancer patients carried enzymatically active CD39 and CD73(+) and, when supplied with eATP, hydrolyzed it to ADO. Only CD4(+) CD39(+) T(reg) co-incubated with CD4(+) CD73(+) T cells, B cells or CD39(+) CD73(+) exosomes produced ADO. Thus, contact with membrane-tethered CD73 was sufficient for ADO production by CD4(+) CD39(+) T(reg). In microenvironments containing CD4(+) CD73(+) T cells, B cells or CD39(+) CD73(+) exosomes, CD73 is readily available to CD4(+) CD39(+) CD73(neg) T(reg) for the production of immunosuppressive ADO.
虽然鼠源 CD4(+) CD39(+) 调节性 T 细胞(T(reg))共表达 CD73 并将外源性(e)三磷酸腺苷(ATP)水解为免疫抑制性腺苷(ADO),但人类循环 CD4(+) CD39(+) T(reg) 表面共表达 CD73 的情况很少见。因此,人类 T(reg) 产生和利用 ADO 进行抑制的能力仍不清楚。使用质谱法,我们测量了来自 30 名志愿者和 14 名癌症患者血液中分离的 CD4(+) CD39(+) 和 CD4(+) CD39(-)CD73(+) T 细胞或 CD19(+) B 细胞的核苷产生情况。通过流式细胞术、Western blot、共聚焦显微镜或逆转录聚合酶链反应(RT-PCR)评估 CD39 和 CD73 的表达。水解外源性 ATP 为 5'-AMP 的循环 CD4(+) CD39(+) T(reg) 含有较少的细胞内颗粒,且 CD73 mRNA 水平较低。这些 T(reg) 中只有约 1%是 CD39(+) CD73(+)。相比之下,CD4(+) CD39(neg) CD73(+) T 细胞的细胞质中含有大量的 CD73(+)颗粒,并强烈表达表面 CD73。体外生成的 T(reg)(Tr1)和大多数 B 细胞都是 CD39(+) CD73(+)。所有这些 CD73(+) T 细胞亚群和 B 细胞都将 5'-AMP 水解为 ADO。从正常对照(NC)或癌症患者的血浆中分离的外泌体携带具有酶活性的 CD39 和 CD73(+),当供应外源性 ATP 时,它会将其水解为 ADO。只有与 CD4(+) CD73(+) T 细胞、B 细胞或 CD39(+) CD73(+) 外泌体共孵育的 CD4(+) CD39(+) T(reg) 才会产生 ADO。因此,与膜结合的 CD73 接触足以使 CD4(+) CD39(+) T(reg) 产生 ADO。在含有 CD4(+) CD73(+) T 细胞、B 细胞或 CD39(+) CD73(+) 外泌体的微环境中,CD73 可被 CD4(+) CD39(+) CD73(neg) T(reg) 用于产生免疫抑制性 ADO。